Moorfields DMO Dataset 003

The Moorfields DMO Dataset encompasses all patients who have received at least one injection of either Lucentis (ranibizumab) or Eylea (aflibercept) to treat diabetic macular oedema (DMO) at Moorfields Eye Hospital - a leading provider of eye health services in the UK and a world-class centre of excellence for ophthalmic research and education.

These therapies began at Moorfields in 2013, however, the dataset will include any imaging or clinical metadata that is available for these patients prior to that time (for example in patients who were initially monitored for the early forms of the disease prior to receiving treatment). Also of note, this dataset will include data from both eyes in each case - for example, it will include data from fellow eyes that are not receiving injections. For these reasons, the dataset will include longitudinal data from a wide range of diabetic eye disease.

Clinical metadata includes information regarding:
- patient demographics
- visual acuities (predominantly measured with Early Treatment Diabetic Retinopathy Study (ETDRS) charts)
- diabetic retinopathy grading
- intravitreal therapies and ocular surgeries

Additional information is provided in the ‘technical details’ tab.

The DMO dataset includes eye imaging modalities, such as:
- Optical coherence tomography (CSO, Heidelberg, Optos, Topcon, Zeiss)
- Colour fundus photographs (Topcon, Zeiss)
- Ultra-wide field photographs (Optos, Zeiss)
- Iris photographs (CSO, Zeiss)
- Keratoscope topography (CSO)
- Infrared photographs (Heidelberg, Topcon, Zeiss)
- Fluorescein angiography (Heidelberg, Optos, Topcon, Zeiss)
- Indocyanine green angiography (Heidelberg, Optos, Topcon)
- Fundus autofluorescence (Heidelberg, Optos, Zeiss)

Imaging data from CSO is subject to additional approvals.

As of July 2024, the dataset consisted of 5,873 eyes receiving Lucentis or Eylea for DMO, over 58,808 injection episodes, and over 1,304,395 ophthalmic images. This is one of the largest single centre databases from patients with DMO and covers more than a decade of follow-up for these patients.